ReviewFood science & nutrition2025
Curcumin's Therapeutic Potential in Ovarian Cancer: Current Insights and Future Perspectives.
Review in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Curcumin induces ferroptosis in ovarian cancer cells through the Nrf2/GPX4 regulation axis.American journal of cancer research · 2026Article
- Curcumin's Therapeutic Potential in Ovarian Cancer: Current Insights and Future Perspectives.Food science & nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer remains the leading cause of gynecological cancer-related mortality in women, highlighting the urgent need for novel therapeutic approaches despite advances in current treatments such as chemotherapy. Curcumin, a natural compound, exhibits potent anticancer properties against ovarian cancer. This review summarizes recent advances in understanding curcumin's role in ovarian cancer therapy. Preclinical studies underscore curcumin's potential as an adjunctive agent, particularly in combination with standard therapies. It enhances treatment efficacy by sensitizing cancer cells to chemotherapy and radiotherapy. Curcumin modulates apoptotic and resistance pathways, inhibits cellular proliferation, and mitigates metastasis in ovarian cancer models. However, the transition from preclinical research to clinical application remains challenging due to the limited number of human trials evaluating curcumin's efficacy, safety profile, and optimal dosage. Recent advancements in delivery systems-such as nanoformulations and lipid-based carriers-aim to improve curcumin's solubility and systemic absorption. These innovations not only enhance curcumin's therapeutic efficacy but also facilitate synergistic combinations with standard chemotherapeutic agents such as cisplatin, thereby improving treatment outcomes and potentially reducing adverse effects. Future research should focus on elucidating curcumin's interactions with ovarian cancer organoids and advancing multi-omics approaches to uncover its epigenetic and therapeutic mechanisms. Addressing these challenges will support the translation of curcumin into an effective therapeutic agent for treating ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.